APSARD’s Lenard A. Adler, MD is featured in a recent New York Post article exploring whether GLP-1 medications like Ozempic could influence ADHD symptoms. While early reports are intriguing, Dr. Adler explains why more research is needed before these medications can be considered part of ADHD treatment.
Read more: https://nypost.com/2026/06/10/health/ozempic-may-be-a-secret-weapon-against-adhd/
A major new study for families with ADHD has been published in the Journal of Clinical Psychiatry. This article examines the complex comorbidities and the unique challenges presented by our patients in clinical practice. This study enrolled not only adults with ADHD but also those experiencing concurrent anxiety, depression, insomnia, and/or cannabis use. The findings demonstrate real-world improvements in mood, anxiety, and sleep when ADHD is better managed.
The APSARD May 2026 Newsletter is now available! Click the button below to access.
The APSARD April 2026 Newsletter is now available! Click the button below to access.
New data challenges clinical hesitation: Treating ADHD, even in patients with substance use disorder, may significantly reduce overdose, suicide risk, and death.
